Search Results - "Carey, Jodi L."

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial by Hillmen, Peter, Prof, Robak, Tadeusz, MD, Janssens, Ann, MD, Babu, K Govind, MD, Kloczko, Janusz, MD, Grosicki, Sebastian, MD, Doubek, Michael, MD, Panagiotidis, Panagiotis, MD, Kimby, Eva, MD, Schuh, Anna, MD, Pettitt, Andrew R, MRCPath, Boyd, Thomas, MD, Montillo, Marco, MD, Gupta, Ira V, MD, Wright, Oliver, BSc, Dixon, Iestyn, BSc, Carey, Jodi L, RN BSN, Chang, Chai-Ni, MS, Lisby, Steen, MD, McKeown, Astrid, PhD, Offner, Fritz, MD

“…Summary Background Treatment for patients with chronic lymphocytic leukaemia who are elderly or who have comorbidities is challenging because fludarabine-based…”
Get full text

Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial by Robak, Tadeusz, Warzocha, Krzysztof, Govind Babu, K., Kulyaba, Yaroslav, Kuliczkowski, Kazimierz, Abdulkadyrov, Kudrat, Loscertales, Javier, Kryachok, Iryna, Kłoczko, Janusz, Rekhtman, Grygoriy, Homenda, Wojciech, Błoński, Jerzy Z., McKeown, Astrid, Gorczyca, Michele M., Carey, Jodi L., Chang, Chai-Ni, Lisby, Steen, Gupta, Ira V., Grosicki, Sebastian

“…In this multicenter, open-label, phase III study, patients with relapsed chronic lymphocytic leukemia (CLL) were randomized (1:1) to receive ofatumumab plus…”
Get full text

Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911) by Hillmen, Peter, Robak, Tadeusz, Janssens, Ann, Govindbabu, K, Grosicki, Sebastian, Mayer, Jiri, Panagiotidis, Panagiotis, Kimby, Eva, Schuh, Anna, Boyd, Thomas, Montillo, Marco, McKeown, Astrid, Carey, Jodi L, Gupta, Ira V, Chang, Chai-Ni, Lisby, Steen, Offner, Fritz

“…▪ Chemoimmunotherapy with purine analogues and the anti-CD20 antibody rituximab is the standard of care as initial therapy in younger and physically fit…”
Get full text